Interim Results

AI SummaryClose X

Oxford BioDynamics Plc reported interim results for the six months ended March 31, 2026, with revenue increasing to £0.69 million from £0.59 million in the prior period, alongside an operating loss of £4.68 million, an improvement from £5.88 million. The company successfully raised £6.32 million after costs in November 2025, boosting cash and term deposits to £2.51 million. Key operational highlights include a 66% increase in PSE test sales and the launch of the EpiSwitch® Orion platform. Richard Compton has been appointed Chief Executive Officer. The company anticipates needing additional funds by late August 2026.

Disclaimer*

UK 100